TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02357771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic (L. brevis CD2 lozenges)
Description: Each Lactobacillus brevis CD2 lozenge contains not less than 1 billion Colony Forming Unit of L. brevis CD2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
Study: NCT00638014

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid Sternal Closure System
Description: Sternal talons will be used and supplemented with wires

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional wire closure
Description: Conventional wire closure of sternum
Study: NCT02109497

Intervention type: DRUG
Group type: OTHER
Intervention: PBT2
Description: PBT2 250 mg administered
Study: NCT02196662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBD98-M:
Description: single adiministration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBD98-M without HA
Description: single adiministration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delzicol
Description: single adiministration
Study: NCT05740501

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical records are reviewed

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03522896

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: balancing sugars and organic acids

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: test meal 1
Description: orange juice plus hesperidin low dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: test meal 2
Description: orange juice plus hesperidin higher dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: test meal 3
Description: diluted orange juice plus hesperidin low dose
Study: NCT04798404

Intervention type: OTHER
Intervention: Multimodal exercise intervention
Description: The intervention conducted was a progressive multicomponent training protocol. The training consisted on 2 collective sessions of 1h per week, during 10 weeks. Sessions involved functional exercises, muscular reinforcement performed at body-weight or with small materials (elastic bands or dumbbells), balance, and adapted sport and physical activities. Progression was based on an increase in workload (or in muscle strains). The workload was considered as the interaction of intensity and volume of exercise (set x repetitions). Intensity was based on effort tolerance, modulate by contraction regimen, velocity and load (elastic bands stiffness). Participants were encouraged to reproduce exercises at home when they were performed easily in supervised collective sessions.
Study: NCT04434456

Intervention type: DEVICE
Intervention: CGuard stent implantation
Description: CGuard stent implantation in the carotid artery with symptomatic, dissecting or enlarging aneurysm
Study: NCT01926561

Intervention type: OTHER
Intervention: Interscalene brachial plexus block
Description: After sterile draping around interscalene groove with povidone, a nerve stimulating needle connected to a nerve stimulator is inserted through the interscalene groove. Following involuntary contraction of shoulder, arm, forearm, or hand muscles with 0.5 milliamperes at 1 Hz using the nerve stimulator, 30 to 40 ml of mixture of 1% mepivacaine 20 ml and 0.75% ropivacaine 20 ml are injected.
Study: NCT00110448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 81 mg or 100 mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No aspirin
Description: No aspirin use
Study: NCT01529567

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy without exposure
Description: 10 week internet-delivered cognitive behavioral therapy, including mindfulness training, education about the negative effects of excessive avoidance and control behaviors on IBS symptoms and quality of life, and guided behavioral change aiming to increase quality of life and flexibility.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy with exposure
Description: 10 week internet-delivered cognitive behavioral therapy, including mindfulness training, education about the negative effects of excessive avoidance and control behaviors on IBS symptoms and quality of life, guided behavioral change aiming to increase quality of life and flexibility, and systematic exposure to IBS symptoms and aversive situations.
Study: NCT02708186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelotanserin
Description: once daily, oral, 20-mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily, oral, matching tablets
Study: NCT01020240

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Avolition
Description: - avolition for cesarean discomforts

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Orientation
Description: * avolition of cesarean discomfort~* physiotherapy orientation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guide
Description: * avolition of cesarean discomfort~* physiotherapy orientation~* guide orientation
Study: NCT01072643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: This is a single center, dose escalation study of Dexmedetomidine in pediatric subjects with pulmonary hypertension (PVR\>4WU) undergoing hemodynamic cardiac catheterization and vasoreactivity drug testing. Cohorts of 8 evaluable subjects will receive dose level 1, dose level 2, or dose level 3 of Dexmedetomidine.
Study: NCT02817464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-46046 - 400 mg/mL
Description: A single subcutaneous injection in the abdomen of undiluted TV-46046 - 400 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-46046 - 200 mg/mL
Description: A single subcutaneous injection in the abdomen of saline-diluted TV-46046 - 200 mg/mL
Study: NCT00540085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: 0.6 mg/kg given intravenously before intubation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: 0.6 mg/kg given intravenously before intubation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: 0.6 mg/kg given intravenously before intubation
Study: NCT05914337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: A program consisting of strengthening and stretching exercises 2 days a week was applied to the study group for 8 weeks. One day a week, 30 minutes of mild moderate walking was requested.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gene expressions of miRNA
Description: In the samples taken, gene expressions of miRNA-146a, miRNA-155, miRNA-16, miRNA-145 were determined by real-time polymerase chain reaction method.
Study: NCT01696188

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: interscalene nerve catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: interscalene nerve catheter
Study: NCT03229785

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Umbilical Cord Blood Plasma
Description: Plasma collected from human umbilical cord blood
Study: NCT02460419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: capecitabine 1250mg/m2 bid, oral, for 14 days, every 3 weeks. Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: OTHER
Group type: OTHER
Intervention: Best supportive care (BSC)
Description: Best supportive care and following-up every 6-8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best supportive care (BSC)
Description: Best supportive care and following-up every 6-8 weeks
Study: NCT03214848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contraceptive education prior to abortion
Description: Contraceptive education script will be delivered over the phone prior to abortion visit.
Study: NCT00888940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecallantide
Description: 2.25 mg/L pump prime, 0.13 mg/kg loading dose, 2.25 mg/L constant infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyklokapron(R)
Description: 1000-mg loading dose followed by a continuous infusion of 400 mg/hr with an additional 500 mg added to the pump prime
Study: NCT02751489

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bain De Soliel - Solid
Description: 0.05 gm/cm2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back. After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.
Study: NCT06330558

Intervention type: PROCEDURE
Intervention: laparoscopic right adrenalectomy
Description: adrenalectomy

Intervention type: PROCEDURE
Intervention: laparoscopic right adrenalectomy
Description: adrenalectomy
Study: NCT05102032

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mini invasive approach
Description: using mini-trocars (3 trocars of 3 mm and a 5 mm-optic trocar) with insufflation pressures of less than 8 mmHg.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional approach
Description: laparoscopic procedure including standard trocars (3 trocars of 5 mm and a 10 mm-optic trocar) with insufflation pressures between 10 and 12 mmHg.
Study: NCT02790190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiotherapy dose
Study: NCT01106248

Intervention type: DRUG
Group type: OTHER
Intervention: Eribulin Mesylate
Description: 1.4 mg/m\^2 intravenous (IV) bolus given over 2-5 minutes on Days 1 and 8 every 21 days.
Study: NCT01694797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol Succinate
Study: NCT04433416

Intervention type: DIAGNOSTIC_TEST
Intervention: hypertension
Description: If the patient has two or more blood pressure values ≥140/90mmHg in a calm state, he is included in this group
Study: NCT03651297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training with Fall-Arrest harness
Description: This study will analyze the subjects' responses to balance training protocols with two types of harness support. The protocol will involve balance training, initially of low intensity and then advanced by an algorithm based on subjects' responses to the prior repetition of balance activity. For this intervention, the subjects will be using a standard Fall-Arrest harness for safety throughout, but no other external support. This will allow comparison of postural control, slip responses, motor learning, reliance on the harness and confidence with the system between the two harness types.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training with Fall-Arrest harness
Description: This study will analyze the subjects' responses to balance training protocols with two types of harness support. The protocol will involve balance training, initially of low intensity and then advanced by an algorithm based on subjects' responses to the prior repetition of balance activity. For this intervention, the subjects will be using a standard Fall-Arrest harness for safety throughout, but no other external support. This will allow comparison of postural control, slip responses, motor learning, reliance on the harness and confidence with the system between the two harness types.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training with Adjustable harness
Description: This study will analyze the subjects' responses to balance training protocols with two types of harness support. The protocol will involve balance training, initially of low intensity and then advanced by an algorithm based on subjects' responses to the prior repetition of balance activity. For this intervention, the subjects will be using a motorized harness in which the support provided is adjustable. This will allow comparison of postural control, slip responses, motor learning, reliance on the harness and confidence with the system between the two harness types.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training with Adjustable harness
Description: This study will analyze the subjects' responses to balance training protocols with two types of harness support. The protocol will involve balance training, initially of low intensity and then advanced by an algorithm based on subjects' responses to the prior repetition of balance activity. For this intervention, the subjects will be using a motorized harness in which the support provided is adjustable. This will allow comparison of postural control, slip responses, motor learning, reliance on the harness and confidence with the system between the two harness types.
Study: NCT02141204

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HRV Liquid
Description: Two doses administered orally according to a 0, 1-month schedule.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HRV Lyophilized
Description: Two doses administered orally according to a 0, 1-month schedule.
Study: NCT01497561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Each subject will be randomly allocated to two dose administrations out of four possible doses. Administrated subcutaneously (s.c., under the skin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin NPH
Description: Each subject will be randomly allocated to two dose administrations out of four possible doses. Administrated subcutaneously (s.c., under the skin)
Study: NCT02454842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-4000 (Tarloxotinib)
Description: TH-4000 (Tarloxotinib) is a hypoxia-activated prodrug
Study: NCT02653599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTP273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTP273

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03313037

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent
Description: Pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13
Description: Pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23
Description: Pneumococcal polysaccharide vaccine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Placebo
Study: NCT02441595

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCP
Description: Eight weekly sessions 2,5 h and homework 30 min/day. Practicing various mindfulness meditations coupled with practical skills and theory of birthing and parenting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoprophylaxis
Description: Three sessions 3h each, and practices to do at home. Practical skills of relaxation and breathing techniques for labor as well as knowledge of birthing and parenting.
Study: NCT03458819

Intervention type: DIAGNOSTIC_TEST
Intervention: Isolation of peritoneal mesothelial cells
Description: HPMCs will be isolated and stored at -80 degrees until analysis. Changes in the protein expression of EMT markers such as E-cadherin, a- SMA, Snail, and fibronectin in the HPMCs will be evaluated by Western blot analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Isolation of peritoneal mesothelial cells
Description: HPMCs will be isolated and stored at -80 degrees until analysis. Changes in the protein expression of EMT markers such as E-cadherin, a- SMA, Snail, and fibronectin in the HPMCs will be evaluated by Western blot analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Isolation of peritoneal mesothelial cells
Description: HPMCs will be isolated and stored at -80 degrees until analysis. Changes in the protein expression of EMT markers such as E-cadherin, a- SMA, Snail, and fibronectin in the HPMCs will be evaluated by Western blot analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Isolation of peritoneal mesothelial cells
Description: HPMCs will be isolated and stored at -80 degrees until analysis. Changes in the protein expression of EMT markers such as E-cadherin, a- SMA, Snail, and fibronectin in the HPMCs will be evaluated by Western blot analysis.
Study: NCT01516021

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: intake of high or low fat yoghurt
Description: intake of 500 ml of a high fat yoghurt on one day and intake of 500 ml of a low fat yoghurt on the other day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: intake of high or low fat yoghurt
Description: intake of 500 ml of a high fat yoghurt on one day and intake of 500 ml of a low fat yoghurt on the other day
Study: NCT00792220

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MSU
Description: In the Mobile Stroke Unit procedure: Conventional Emergency Medical Service together with the MSU will meet at the side, where the patient is found. The MSU is an ambulance, equipped with a neurologist and neuroradiologist and includes CT scanner and point of care laboratory unit. The patient's medical history and the physical examination will be directly performed by the neurologist. CT scan analysis will be performed by the neuroradiologist, while the neurologist will analyze the blood samples with the point of care laboratory unit. If the inclusion and exclusion criteria are fulfilled, the thrombolytic therapy will directly be started by the neurologist. A possible thrombolytic therapy will be performed under the current inclusion and exclusion criteria that are associated with the rt-PA drug approval in Europe. After performance of the acute therapy, the patient will be transported to the University Hospital of the Saarland.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OCCM
Description: In the optimized conventional clinical management: After patient's medical history, physical examination and emergency treatment by the emergency physician, the patient will be transported to the University Hospital of the Saarland. The delivery of the patient will directly take place at the CT scanner. The neurologist will perform a second medical history, physical examination, while the blood will be drawn by the assisting nurse. CT scan will be performed, while the blood will be analyzed by point of care technique, placed close to the CT scanner. Additionally the blood will be sent in parallel to the hospital central laboratory for conventional laboratory analysis. Depending on the results, a thrombolytic therapy will be initiated directly at the CT. Thereafter, the patient will be transported to the hospital Stroke Unit.
Study: NCT01982656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: twenty minute massage intervention prior to bedtime (1900-2100), to be started after day 3 of admission for a minimum of 5 consecutive days and up to fourteen days. The massage will be conducted by an RN trained in massage technique that is not caring for the patient in a direct nursing role.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Massage
Description: twenty minute massage intervention prior to bedtime (1900-2100), to be started after day 3 of admission for a minimum of 5 consecutive days and up to fourteen days. The massage will be conducted by an RN trained in massage technique that is not caring for the patient in a direct nursing role.
Study: NCT03074838

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial aortic valve implantation - TAVI
Description: After insertion of a guidewire, either through the femoral artery or through the ascending aorta, the aortic ostium is dilated by a balloon and the valve is introduced through a catheter and expanded in the ostium.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical aortic valve replacement - SAVR
Description: The patient is operated through a sternotomy and coupled to a heart lung machine. The aorta is opened and the native valve excised. Then a biological artificial heart valve is sutured in place.
Study: NCT00693771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Once daily and up-titrate accordingly
Study: NCT00654550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexagon™ or Nexagon™ vehicle
Description: Dose-escalation design in which cohorts of 6 subjects will be studied sequentially.
Study: NCT04163211

Intervention type: PROCEDURE
Intervention: Abdominal drain
Description: A latex-free drain (size 20F)

Intervention type: PROCEDURE
Intervention: Abdominal drain
Description: A latex-free drain (size 20F)
Study: NCT00636298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab, cetuximab
Description: Cetuximab - 400 mg/m2 loading, then 250 mg/m2 weekly~Bevacizumab - 10 mg/kg every 2 weeks
Study: NCT00355966

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: In one group of women immediate induction of labour will be done by intravaginal misoprostol 25 microgram 4 hourly , a maximum of 5 doses .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PGE2 gel
Description: In other group immediate induction of labour will be done by intravaginal application of PGE2 gel 0.5 mg at an interval of 6 hours , a maximum of 2 doses.
Study: NCT00397865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational booklet
Description: Parental perception of educational booklet and evaluating any change in child's weight.
Study: NCT00569959

Intervention type: OTHER
Group type: OTHER
Intervention: fasting 12+ hours
Description: fasting 12+ hours

Intervention type: OTHER
Group type: OTHER
Intervention: Non-fasting
Description: Non-fasting
Study: NCT02510508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group CRAFT
Description: CSOs will receive seven weekly 90 min sessions of CRAFT + Self-Directed CRAFT Delivery

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Directed CRAFT Delivery
Description: CRAFT self-help book (Self Directed CRAFT Delivery)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-intervention
Description: Non-intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-intervention
Description: Non-intervention
Study: NCT02219425

Intervention type: PROCEDURE
Group type: OTHER
Intervention: endometrial biopsy
Study: NCT02694289

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Treatment/continuation of metformin therapy during admission

Intervention type: DRUG
Group type: OTHER
Intervention: Subcutaneous (sliding scale) Insulin
Description: Discontinue Metformin and be placed on subcutaneous sliding scale insulin during admission